Investigating the relationship of BRAF and psuda BRAF genetic polymorphism in leukemia

Leukemia is the cancer of the body's blood-forming processes, including the bone marrow and lymphatic systems. There are many types of leukemia. Some forms of leukemia are more common among children, while other forms of leukemia often affect adults. This study aims to detect the prevalence of V600E pathogenic mutations and other mutations in the BRAF gene and PBRAF that cause leukemia. In this study, BRAFP1 was looked at in 14 people with leukemia. This was done to find and record new polymorphisms that cause leukemia, as well as to figure out the genetic change and how it affects the normal function of the gene. 19 samples were collected at the Medical City Hospital in Baghdad between June 2022 and September 2022. The samples were divided into two groups. The first group was made up of 14 leukemia patients. And the second group had five samples as a control group (normal individuals). Each participant provided a single blood sample in a container with a mouth-tight lid and a capacity of 5 mL for the study. Standard phlebomy procedures were followed to collect blood samples from volunteers. These samples were placed in 5 mL ethylenediamine tetraacetic acid tubes. There were significant differences in the DNA sequence of the BRAF gene that could be seen among patients; second, no difference could be observed among normal or control patients. Nine patients showed the highest divergence in the BRAF gene sequence among patients. Upon examining the difference in colors of squares in the matrix, patients showed almost the same percentage of difference in the BRAF DNA sequence of 73%–79%, indicating a common change at a specific location that will be investigated. While BRAFP1 compares results between control and patients, the following conclusion can be drawn: first, there is a specific difference in similarity among patients since the score generated did not exceed 60%. Comparing patients with normal, the score generated is about 99%. This can be explained on the basis of the position of the sequence aligned in patients; second, when patients sequences were aligned with control, only a few changes in the sequence were observed, which means there are specific changes at certain positions in BRAFP1, the gene in patients with leukemia.